“Sanofi (NASDAQ:SNY) expects to move to a large late-stage trial with an experimental coronavirus vaccine toward the end of the year,” said CEO Paul Hudson at a conference in France.
If proved to be effective, the Company will ship the vaccine to U.S., Europe and France.
Sanofi has teamed up with GlaxoSmithKline (NYSE:GSK) to develop a COVID-19 vaccine. A Phase 1/2 clinical trial is expected in September, followed by a Phase 3 by year-end.
If all goes well, SNY will file a marketing application in H1 2021.
Selected tickers: Pfizer (PFE -0.4%); Merck (MRK -0.3%); Johnson & Johnson (JNJ -0.1%); Moderna (MRNA -3.7%); Novavax (NVAX -1.7%); Dynavax (DVAX -0.8%); BioNTech SE (BNTX +0.6%); AstraZeneca (AZN -0.8%); Inovio Pharmaceuticals (INO -3.7%); iBio (IBIO -3.6%); Vaxart (VXRT -3.2%); VBI Vaccines (VBIV +48.9%)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.